Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

3

Revenue 2017

MabThera/Rituxan

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. MabThera/Rituxan was produced by Roche.

NICE backs Cancer Drugs Fund support for Roche's Gazyvaro

NICE backs Cancer Drugs Fund support for Roche's Gazyvaro on Roche's MabThera (rituximab) - and as monotherapy for maintenance thereafter - via the CDF. ... Like MabThera, Gazyvaro targets the CD20 receptor but has been designed with sugar molecule side chains that improve its therapeutic and safety profile.

Standing out in a crowd

Standing out in a crowd Celltrion’s current focus, he said, is immunology and oncology. With biosimilars of Remicade and Mabthera already approved in Europe, the next in line for a licence is likely to be ... versions of MabThera and Herceptin.

Sandoz joins Europe's MabThera biosimilar push

Sandoz joins Europe's MabThera biosimilar push Novartis' Sandoz unit has become the second company to claim approval in Europe for a biosimilar version of Roche's blockbuster immunotherapy drug MabThera. ... MabThera is celebrating its 20th year on the market this year, and has been a massive earner

Payback time nears as Sanofi gets CHMP backing for biosimilar Humalog

Payback time nears as Sanofi gets CHMP backing for biosimilar Humalog The CHMP also backed three biosimilars of Roche's Rituxan (rituximab) developed by Celltrion namely Blitzima, Tuxella and Ritemvia.

WHO pilots scheme to make biosimilars available to poorer countries

WHO pilots scheme to make biosimilars available to poorer countries Plans to expand prequalification scheme to medicines such as Roche’s Rituxan and Herceptin. ... In the latest move the WHO says it will focus on biosimilar medicines, starting with Roche's widely-used cancer drugs MabThera/Rituxan (rituximab) and

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics